v3.26.1
Note 11 - Stock-Based Compensation (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Feb. 20, 2026
Jan. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) [1]     2,228,500    
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) [1]     $ 1.35    
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)     242,284 203,051  
Proceeds from Stock Plans     $ 210 $ 141  
Restricted Stock [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     5,746,000    
Lucid Diagnostics 2018 Equity Plan [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares)     26,603,181    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)     976,335    
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 2,161,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)   8,260,980      
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) $ 1.36        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)     $ 0.84 $ 0.94  
Lucid Diagnostics 2018 Equity Plan [Member] | Restricted Stock [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 5,746,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value $ 7,800        
Lucid Diagnostics 2018 Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)     10 years    
Lucid Diagnostics 2018 Equity Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Tranche One [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage 0.33%   0.33%    
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)     1 year    
PAVmed 2014 Equity Plan [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)     523,300   523,300
PAVmed 2014 Equity Plan [Member] | Restricted Stock [Member]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)     50,000    
Lucid ESPP [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares)     3,500,000    
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)     1,662,087    
[1] Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant.